Furthermore, the authors suggest the combination of PD-L1 with other new biomarkers, such as tumor mutational burden or immune cell infiltration, will be required for an optimal personalized patient ́s selection, which might improve the outcomes (even gender-specific ones) (Eckstein et al. 2019). This evidence concerns the gene CD274 and neoplasm.